168 related articles for article (PubMed ID: 24388920)
21. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial.
van de Laar RLO; Hofhuis W; Duijnhoven RG; Polinder S; Melchers WJG; van Kemenade FJ; Bekkers RLM; Van Beekhuizen HJ
BMC Cancer; 2020 Jun; 20(1):539. PubMed ID: 32517663
[TBL] [Abstract][Full Text] [Related]
22. A controlled trial of a human papillomavirus type 16 vaccine.
Koutsky LA; Ault KA; Wheeler CM; Brown DR; Barr E; Alvarez FB; Chiacchierini LM; Jansen KU;
N Engl J Med; 2002 Nov; 347(21):1645-51. PubMed ID: 12444178
[TBL] [Abstract][Full Text] [Related]
23. Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial.
Zhao S; Hu S; Xu X; Zhang X; Pan Q; Chen F; Zhao F
BMC Infect Dis; 2020 Nov; 20(1):846. PubMed ID: 33198657
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years.
Yoshikawa H; Ebihara K; Tanaka Y; Noda K
Cancer Sci; 2013 Apr; 104(4):465-72. PubMed ID: 23331518
[TBL] [Abstract][Full Text] [Related]
25. Human papillomavirus and Papanicolaou tests to screen for cervical cancer.
Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Johansson B; Forslund O; Hansson BG; Rylander E; Dillner J
N Engl J Med; 2007 Oct; 357(16):1589-97. PubMed ID: 17942872
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia.
Schlecht NF; Platt RW; Duarte-Franco E; Costa MC; Sobrinho JP; Prado JC; Ferenczy A; Rohan TE; Villa LL; Franco EL
J Natl Cancer Inst; 2003 Sep; 95(17):1336-43. PubMed ID: 12953088
[TBL] [Abstract][Full Text] [Related]
27. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
[TBL] [Abstract][Full Text] [Related]
28. Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
Lovera J; Ramos A; Devier D; Garrison V; Kovner B; Reza T; Koop D; Rooney W; Foundas A; Bourdette D
J Neurol Sci; 2015 Nov; 358(1-2):46-52. PubMed ID: 26298797
[TBL] [Abstract][Full Text] [Related]
29. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of Specific Types of Human Papiloma Virus in Cervical Intraepithelial Lesions and Cervical Cancer in Macedonian Women.
Aleksioska-Papestiev I; Chibisheva V; Micevska M; Dimitrov G
Med Arch; 2018 Feb; 72(1):26-30. PubMed ID: 29416214
[TBL] [Abstract][Full Text] [Related]
31. A pilot study to evaluate the safety and efficacy of an oral dose of (-)-epigallocatechin-3-gallate-rich polyphenon E in patients with mild to moderate ulcerative colitis.
Dryden GW; Lam A; Beatty K; Qazzaz HH; McClain CJ
Inflamm Bowel Dis; 2013 Aug; 19(9):1904-12. PubMed ID: 23846486
[TBL] [Abstract][Full Text] [Related]
32. Randomized, placebo-controlled trial evaluating the safety of one-year administration of green tea catechins.
Kumar NB; Pow-Sang J; Spiess PE; Park J; Salup R; Williams CR; Parnes H; Schell MJ
Oncotarget; 2016 Oct; 7(43):70794-70802. PubMed ID: 28053292
[TBL] [Abstract][Full Text] [Related]
33. Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention.
Kumar NB; Pow-Sang J; Egan KM; Spiess PE; Dickinson S; Salup R; Helal M; McLarty J; Williams CR; Schreiber F; Parnes HL; Sebti S; Kazi A; Kang L; Quinn G; Smith T; Yue B; Diaz K; Chornokur G; Crocker T; Schell MJ
Cancer Prev Res (Phila); 2015 Oct; 8(10):879-87. PubMed ID: 25873370
[TBL] [Abstract][Full Text] [Related]
34. Polyphenon E: a new treatment for external anogenital warts.
Tatti S; Stockfleth E; Beutner KR; Tawfik H; Elsasser U; Weyrauch P; Mescheder A
Br J Dermatol; 2010 Jan; 162(1):176-84. PubMed ID: 19709100
[TBL] [Abstract][Full Text] [Related]
35. Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
Giuliano AR; Joura EA; Garland SM; Huh WK; Iversen OE; Kjaer SK; Ferenczy A; Kurman RJ; Ronnett BM; Stoler MH; Bautista OM; Moeller E; Ritter M; Shields C; Luxembourg A
Gynecol Oncol; 2019 Jul; 154(1):110-117. PubMed ID: 30982556
[TBL] [Abstract][Full Text] [Related]
36. Utility of human papillomavirus L1 capsid protein and HPV test as prognostic markers for cervical intraepithelial neoplasia 2+ in women with persistent ASCUS /LSIL cervical cytology.
Ki EY; Park JS; Lee A; Kim TJ; Jin HT; Seo YB; Gen Y; Park MY; Lee SJ
Int J Med Sci; 2019; 16(8):1096-1101. PubMed ID: 31523171
[No Abstract] [Full Text] [Related]
37. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study.
Jaisamrarn U; Castellsagué X; Garland SM; Naud P; Palmroth J; Del Rosario-Raymundo MR; Wheeler CM; Salmerón J; Chow SN; Apter D; Teixeira JC; Skinner SR; Hedrick J; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; de Carvalho NS; Germar MJ; Peters K; Paavonen J; Bozonnat MC; Descamps D; Struyf F; Dubin GO; Rosillon D; Baril L;
PLoS One; 2013; 8(11):e79260. PubMed ID: 24260180
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double blind, Phase III trial using oral beta-carotene supplementation for women with high-grade cervical intraepithelial neoplasia.
Keefe KA; Schell MJ; Brewer C; McHale M; Brewster W; Chapman JA; Rose GS; McMeeken DS; Lagerberg W; Peng YM; Wilczynski SP; Anton-Culver H; Meyskens FL; Berman ML
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1029-35. PubMed ID: 11588128
[TBL] [Abstract][Full Text] [Related]
40. Impact of the human papillomavirus status on the development of high-grade cervical intraepithelial neoplasia in women negative for intraepithelial lesions or malignancy at the baseline: A 9-year Swedish nested case-control follow-up study.
Fröberg M; Östensson E; Belkić K; Oštrbenk A; Poljak M; Mints M; Arbyn M; Andersson S
Cancer; 2019 Jan; 125(2):239-248. PubMed ID: 30536370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
